Irinotecan in Treating Patients With Recurrent or Refractory Non-Hodgkin's Lymphoma

Completed · Phase 2

Conditions studied: Lymphoma

In brief

RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of irinotecan in treating patients with recurrent or refractory non-Hodgkin's lymphoma.

Key facts

Study ID

NCT00003245

Run by

M.D. Anderson Cancer Center

People needed

50

Starts

1998-02-18

Expected to finish

2004-07-30

Last updated by the study team

2018-11-15

Who can join

Age: 15 and older, up to 75. Sex: any. Healthy volunteers: not accepted.

Where it is running

• University of Texas - MD Anderson Cancer Center — Houston, Texas, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.